Moreover, this panel was superior to PSA in distinguishing PCa from controls when PSA levels were less than 20 ng/ml [AUC (MET vs. PSA): 0.836 ± 0.050 vs. 0.656 ± 0.067, p<0.001; Figure 3A] or less than 10 ng/ml [AUC (MET vs. PSA): 0.909 ± 0.060 vs. 0.519 ± 0.101, p<0.001; Figure 3B]. The gene discussed is KLK3; the disease is posterior cortical atrophy.